ArticlePloS one2015
The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2025Pooled it
- Geographic Disparities in Access to Glaucoma Surgery: Lessons from a Nationwide Registry Study.Journal of clinical medicine · 2026Article
- Systemic and ocular factors determining the circumpapillary retinal nerve fibre layer thickness in an unselected adult population.BMJ open ophthalmology · 2026Article
- The incidence rates and prevalence of treated glaucoma in the United Kingdom, 2000-2022.PloS one · 2026Article
- The role of general practice in the identification of age-related vision impairment and chronic eye diseases: a systematic review.BJGP open · 2025Article
- Socioeconomic factors and the risk of eye diseases in an elderly Danish population.Journal of epidemiology and community health · 2025Article
- Users of reimbursed glaucoma medications in Finland in 1986-2023: A nationwide study.Acta ophthalmologica · 2025Article
- Review
- Effects of Anatomical Variation on Ganglion Cell and Nerve Fibre Layer Evaluation by Optical Coherence Tomography.Journal of clinical medicine · 2024Article
- Predictors and long-term patterns of medication adherence to glaucoma treatment in Denmark-an observational registry study of 30 100 Danish patients with glaucoma.BMJ open ophthalmology · 2024Article
- Effect of antihypertensive medications on the risk of open-angle glaucoma.Scientific reports · 2023Article
- Relative Importance of Glaucoma-Referral Indicators in Retinal Images in a Diabetic Retinopathy Screening Programme in Slovenia: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2023Article
- Five-year incidence of primary glaucoma and related risk factors - The Handan eye study.Acta ophthalmologica · 2023Article
- Inferring glaucoma status from prescriptions, diagnoses, and operations data: A Danish nationwide study.PloS one · 2023Article
- Synthesis and Molecular Docking of New N-Acyl Hydrazones- Benzimidazole as hCA I and II Inhibitors.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2023Article
- Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquarternium-1-preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties.Acta ophthalmologica · 2022Article
- Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan.Journal of personalized medicine · 2022Article
- Role of Oxidative Stress in Retinal Disease and the Early Intervention Strategies: A Review.Oxidative medicine and cellular longevity · 2022Review
- Girl Power in Glaucoma: The Role of Estrogen in Primary Open Angle Glaucoma.Cellular and molecular neurobiology · 2022Review
- Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?Frontiers in neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of the present study was to describe the prevalence, incidence and geographic variation of glaucoma in Denmark in the period from 1996 to 2011. Moreover, the aim was to identify the treatment patterns of glaucoma within the studied period.
methodsAll Danish citizens were included throughout the study period. The National Prescription Registry was used to identify all claimed prescriptions for glaucoma medication.
resultsA total of 116,592 incident glaucoma patients were identified. Average age at onset was 66 years (range: 0-105 years), 55% were women. The prevalence of glaucoma increased from 0.79% to 1.72% during the investigated period. In 2011 glaucoma affected 3.76% of the population above 50 years and 10% in patients above 80 years. The age-specific incidence rate of glaucoma seemed to be constant and the increasing prevalence was primarily attributed to an aging population. We found the highest prevalence of glaucoma in the capital region of Denmark. Within the studied period the use of prostaglandin analogs and combination drugs increased, whereas the use of β-blockers, carbon anhydrase inhibitors and parasympathomimetic drugs decreased (p<0.001). Finally, the use of α2-adrenergic agonists remained unchanged. A total of 75% of the patients were treated with two or more glaucoma medications.
conclusionsOver all, the present study is the first to assess the frequency and the development of glaucoma in Denmark over a 15-year period. We find that glaucoma affects a little less than 2% of the total population and increases with age to reach a prevalence of more than 10% amongst people above 80 years. Generally, the present study is the largest nation-wide study ever made and must be a close-to-real-life-picture of the utilization of glaucoma medication on a national scale. Our findings confirm other recent estimations on an increasing burden of glaucoma globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.